SeQuent Scientific Ltd
NSE:SEQUENT

Watchlist Manager
SeQuent Scientific Ltd Logo
SeQuent Scientific Ltd
NSE:SEQUENT
Watchlist
Price: 193.73 INR 0.6% Market Closed
Market Cap: 48.9B INR

Relative Value

The Relative Value of one SEQUENT stock under the Base Case scenario is 166.52 INR. Compared to the current market price of 193.73 INR, SeQuent Scientific Ltd is Overvalued by 14%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SEQUENT Relative Value
Base Case
166.52 INR
Overvaluation 14%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
33
vs Industry
48
Median 3Y
2.3
Median 5Y
2.5
Industry
2.7
vs History
28
vs Industry
1
Median 3Y
143.8
Median 5Y
82.5
Industry
21.4
vs History
58
vs Industry
3
Median 3Y
64.4
Median 5Y
64.4
Industry
16.8
vs History
vs Industry
2
Median 3Y
-140.7
Median 5Y
-71.7
Industry
23.1
vs History
23
vs Industry
14
Median 3Y
5.1
Median 5Y
5.2
Industry
2.3
vs History
30
vs Industry
44
Median 3Y
2.5
Median 5Y
2.6
Industry
2.9
vs History
30
vs Industry
38
Median 3Y
5.6
Median 5Y
5.8
Industry
5.5
vs History
66
vs Industry
15
Median 3Y
35.1
Median 5Y
33.2
Industry
13.3
vs History
50
vs Industry
9
Median 3Y
51.5
Median 5Y
51.5
Industry
16.5
vs History
58
vs Industry
3
Median 3Y
67.3
Median 5Y
67.3
Industry
16
vs History
9
vs Industry
4
Median 3Y
-27.8
Median 5Y
-28.7
Industry
18.9
vs History
25
vs Industry
25
Median 3Y
2.9
Median 5Y
3.2
Industry
2

Multiples Across Competitors

SEQUENT Competitors Multiples
SeQuent Scientific Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
SeQuent Scientific Ltd
NSE:SEQUENT
48.5B INR 3 163.4 30.7 51.2
US
Eli Lilly and Co
NYSE:LLY
982.2B USD 16.5 53.3 35.8 38.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
526.1B USD 5.7 20.9 17.1 22.2
CH
Roche Holding AG
SIX:ROG
277.8B CHF 4.5 29.5 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
217.9B GBP 5 31 108.8 159.2
CH
Novartis AG
SIX:NOVN
221.8B CHF 4.9 19.2 12.1 15.7
US
Merck & Co Inc
NYSE:MRK
270.7B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.5 16.6 11.6 13.4
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
145.8B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
IN
SeQuent Scientific Ltd
NSE:SEQUENT
Average P/E: 40.3
163.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.3
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.5
29%
1
UK
AstraZeneca PLC
LSE:AZN
31
37%
0.8
CH
Novartis AG
SIX:NOVN
19.2
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
16.6
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
SeQuent Scientific Ltd
NSE:SEQUENT
Average EV/EBITDA: 402.8
30.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.8
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17.1
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12.1
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.6
1%
11.6
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
SeQuent Scientific Ltd
NSE:SEQUENT
Average EV/EBIT: 1 717.1
51.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.4
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.2
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
CH
Novartis AG
SIX:NOVN
15.7
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5